HOME >> BIOLOGY >> NEWS
New Medication Means New Choices For Families Dealing With Alzheimers Disease

Hershey, Pa. -- A new study from Penn State's College of Medicine finds that when medication for Alzheimer's disease is offered to all patients, family members of patients in the early stages of Alzheimer's are the most likely to accept available treatment.

"When dealing with this terrible disease, families are faced with many extremely difficult decisions. One of those decisions is whether or not to treat their ill family member with this relatively new drug, that doesn't stop the disease, but slows the progression of the disease," says Paul Kettl, M.D., associate professor of psychiatry and acting chair of psychiatry at Penn State. Kettl is also chief of psychiatry with the Penn State Geisinger Health System in Hershey, Pa.

The results of the one-year study titled, "Family Treatment Decisions in Alzheimer's Disease," was presented today (June 3) at the American Psychiatric Association meeting in Toronto.

Kettl studied 60 patients with Alzheimer's disease who were admitted consecutively to the inpatient psychiatry unit at Hershey Medical Center. The one-year study asked families whether or not they wanted the patient to be treated with the drug donepezil or vitamin E. Both treatments do not stop the disease but significantly slow the progress of the disease. Donepezil has been widely prescribed by physicians for about a year.

"There were 28 people in the treatment group and 32 people in the non-treatment group. We found there was no difference based on age or sex," says Kettl. "The difference in treatment decisions was determined more by how far the disease had progressed. For patients who were in the early stages of the disease and often were cared for at home, families overwhelmingly chose to treat the patient. For those patients who lived in a nursing home and the disease was fairly advanced, families chose to withhold the treatment."

Kettl says these kinds of difficult ethical questions will have to
'"/>

Contact: Leilyn Perri
lperri@psghs.edu
717-531-8604
Penn State
3-Jun-1998


Page: 1 2

Related biology news :

1. Medication reconciliation, pharmacist involvement vital to reducing medication errors, study finds
2. Possible Dangers Of Taking Over-The-Counter Medications For Hepatitis C Patients
3. Common Anti-Viral Medication Prevents Severe Eye Herpes
4. Study Reviews Medication Use In Elderly Cardiac Patients After Discharge
5. Material Choices For The Chemical Industry
6. Families with severe form of bipolar disorder help scientists narrow the search for disease genes
7. Families with two or more children with autism sought for $10.2 million study
8. Sudden Cardiac Death May Run In Families
9. Vastly Different Virus Families May Be Related
10. Dealing with reams of data
11. New theory of cell death proposed in UCSB Alzheimers research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused ... Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine ... and is expected to deliver therapeutic levels of olanzapine for a period of 3 ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
Cached News: